Optimal control of cyclophosphamide-induced emesis

Area of Science:

• Oncology
• Pharmacology

Background:

• Cyclophosphamide is a widely used chemotherapeutic agent.
• It is known to induce moderate to severe emesis (vomiting).
• The severity of emesis is dose-dependent and influenced by combination chemotherapy regimens.

Purpose of the Study:

• To review and synthesize existing literature on antiemetic therapies for cyclophosphamide-induced emesis.
• To identify optimal antiemetic strategies based on cyclophosphamide dosage and drug combinations.

Main Methods:

• Literature review of studies on antiemetic therapy for cyclophosphamide.
• Categorization of studies by cyclophosphamide dose and cytotoxic drug combinations.
• Evaluation of antiemetic efficacy for different chemotherapy regimens.

Main Results:

• Ondansetron plus dexamethasone provides optimal antiemetic therapy for standard or high-dose cyclophosphamide (≥ 450 mg/m²).
• Prolonged antiemetic coverage is crucial for regimens like intravenous CMF/(F)AC/(F)EC.
• For low-dose oral CMF chemotherapy, oral ondansetron or oral metoclopramide with intravenous/oral dexamethasone are effective.

Conclusions:

• Antiemetic selection should be tailored to cyclophosphamide dose and chemotherapy regimen.
• Combination therapy with ondansetron and dexamethasone is highly effective for high-dose cyclophosphamide.
• Appropriate antiemetic strategies are essential for managing nausea and vomiting in cancer patients receiving cyclophosphamide.